- Home
- HOMB vs MIRM Comparison
HOMB vs MIRM Comparison
Compare HOMB & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HOMB | MIRM |
|---|---|---|
| Founded | 1998 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6B | 5.7B |
| IPO Year | 2006 | 2019 |
Fundamental Metrics
Financial Performance| Metric | HOMB | MIRM |
|---|---|---|
| Price | $26.69 | $95.97 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 12 |
| Target Price | $32.40 | ★ $115.33 |
| AVG Volume (30 Days) | ★ 1.2M | 788.7K |
| Earning Date | 04-15-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.04% | N/A |
| EPS Growth | 19.90 | ★ 74.59 |
| EPS | ★ 2.41 | N/A |
| Revenue | N/A | ★ $19,138,000.00 |
| Revenue This Year | $10.99 | $26.22 |
| Revenue Next Year | $5.14 | $22.04 |
| P/E Ratio | $11.46 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $25.68 | $38.22 |
| 52 Week High | $30.83 | $109.28 |
Technical Indicators
Market Signals| Indicator | HOMB | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 41.60 | 52.36 |
| Support Level | $26.10 | $85.35 |
| Resistance Level | $27.49 | $98.03 |
| Average True Range (ATR) | 0.51 | 3.62 |
| MACD | 0.06 | 0.44 |
| Stochastic Oscillator | 17.27 | 67.06 |
Price Performance
Historical ComparisonAbout HOMB Home BancShares Inc.
Home BancShares Inc is a bank holding company that operates through its wholly owned community bank subsidiary, Centennial Bank. The bank provides a broad range of commercial and retail banking, as well as related financial services, to a diverse customer base. Its customer base includes businesses, real estate developers and investors, individuals, and municipalities. The company's loan portfolio, while diversified, is typically between half and two thirds in commercial real estate loans. The company's plan emphasizes growth, both through strategic acquisitions and organically within its existing markets. The company has one reportable segment: The Banking Segment.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.